Sunshine Biopharma Inc Quick Ratio (SBFM) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sunshine Biopharma Inc   (NASDAQ: SBFM)

Sunshine Biopharma Inc 's Quick Ratio

SBFM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Sunshine Biopharma Inc 's Cash & cash equivalent grew by 292.36 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Sunshine Biopharma Inc 's Quick Ratio to 0.05, Quick Ratio remained below Sunshine Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Sunshine Biopharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3898 to 3974.

Explain Quick Ratio?
How much Cash & cash equivalents SBFM´s has?
What are SBFM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SBFM Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 0.81 % 2.01 % 2.04 % 50.75 % 5.18 %
Y / Y Cash & cash equivalent Change - 1.82 % - - -
Quick Ratio MRQ 0.05 0.01 - - -
SBFM's Total Ranking # 3974 # 3898 # 0 # 0 # 0
Seq. Current Liabilities Change -4.41 % -8.78 % -3.12 % 19.33 % -3.27 %
Seq. Cash & cash equivalent Change 292.36 % - - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 431
Healthcare Sector # 867
Overall Market # 3974


Quick Ratio Statistics
High Average Low
398.62 22.71 0.01
(Jun 30 2022)   (Mar 31 2026)




Financial Statements
Sunshine Biopharma Inc 's Current Liabilities $ 6 Millions Visit SBFM's Balance sheet
Sunshine Biopharma Inc 's Cash & cash equivalent $ 0 Millions Visit SBFM's Balance sheet
Source of SBFM's Sales Visit SBFM's Sales by Geography


Cumulative Sunshine Biopharma Inc 's Quick Ratio

SBFM's Quick Ratio for the trailling 12 Months

SBFM Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 11.46 % 12.66 % 8.3 % 11.49 % -1.82 %
Y / Y Cash & cash equivalent TTM Growth 401.33 % 1.82 % - - -
Quick Ratio TTM 0.01 0 0 0 0
Total Ranking TTM # 4189 # 3219 # 3182 # 2569 # 2942
Seq. Current Liabilities TTM Growth 0.18 % 0.47 % 0.53 % 10.15 % 1.26 %
Seq. Cash & cash equivalent TTM Growth 392.36 % 1.82 % 0 % 0 % 0 %

Quick ratio ranking by company, industry and sector >> Back to SBFM Financial Strength Comparisons >> Go to Compare SBFM Quick Ratio to its Competitors

On the trailing twelve months basis SBFM Cash & cash equivalent more than doubled by 292.36 % in Q2 2026 year on year, faster than Current Liabilities, this led to